Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients
Top Cited Papers
- 1 June 2008
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 31 (6) , 1224-1229
- https://doi.org/10.2337/dc07-2013
Abstract
OBJECTIVE—The aims of this study were to determine the incidence of diabetes among HIV-infected patients in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort, to identify demographic, HIV-related, and combination antiretroviral therapy (cART)-related factors associated with the onset of diabetes, and to identify possible mechanisms for any relationships found. RESEARCH DESIGN AND METHODS—D:A:D is a prospective observational study of 33,389 HIV-infected patients; diabetes is a study end point. Poisson regression models were used to assess the relation between diabetes and exposure to cART after adjusting for known risk factors for diabetes, CD4 count, lipids, and lipodystrophy. RESULTS—Over 130,151 person-years of follow-up (PYFU), diabetes was diagnosed in 744 patients (incidence rate of 5.72 per 1,000 PYFU [95% CI 5.31–6.13]). The incidence of diabetes increased with cumulative exposure to cART, an association that remained significant after adjustment for potential risk factors for diabetes. The strongest relationship with diabetes was exposure to stavudine; exposures to zidovudine and didanosine were also associated with an increased risk of diabetes. Time-updated measurements of total cholesterol, HDL cholesterol, and triglycerides were all associated with diabetes. Adjusting for each of these variables separately reduced the relationship between cART and diabetes slightly. Although lipodystrophy was significantly associated with diabetes, adjustment for this did not modify the relationship between cART and diabetes. CONCLUSION—Stavudine and zidovudine are significantly associated with diabetes after adjustment for risk factors for diabetes and lipids. Adjustment for lipodystrophy did not modify the relationship, suggesting that the two thymidine analogs probably directly contribute to insulin resistance, potentially through mitochondrial toxicity.Keywords
This publication has 23 references indexed in Scilit:
- Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV StudyAIDS, 2007
- Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort StudyClinical Infectious Diseases, 2007
- Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adultsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort StudyArchives of internal medicine (1960), 2005
- Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 DiabetesNew England Journal of Medicine, 2004
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2003
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003
- Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in HIV LipodystrophyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000